Size and methylation mosaicism in males with Fragile X syndrome

Poonnada Jiraanont, Madhur Kumar, Hiu Tung Tang, Glenda Espinal, Paul J Hagerman, Randi J Hagerman, Nuanchan Chutabhakdikul, Flora Tassone

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Size and methylation mosaicism are a common phenomenon in Fragile X syndrome (FXS). Here, the authors report a study on twelve fragile X males with atypical mosaicism, seven of whom presented with autism spectrum disorder. Methods: A combination of Southern Blot and PCR analysis was used for CGG allele sizing and methylation. FMR1 mRNA and FMRP expression were measured by qRT-PCR and by Homogeneous Time Resolved Fluorescence methodology, respectively. Results: DNA analysis showed atypical size- or methylation-mosaicism with both, full mutation and smaller (normal to premutation) alleles, as well as a combination of methylated and unmethylated alleles. Four individuals carried a deletion of the CGG repeat and portions of the flanking regions. The extent of methylation among the participants was reflected in the lower FMR1 mRNA and FMRP expression levels detected in these subjects. Conclusion: Decreased gene expression is likely the main contributor to the cognitive impairment observed in these subjects; although the presence of a normal allele did not appear to compensate for the presence of the full mutation, it correlated with better cognitive function in some but not all of the reported cases emphasizing the complexity of the molecular and clinical profile in FXS.

Original languageEnglish (US)
Pages (from-to)1023-1032
Number of pages10
JournalExpert Review of Molecular Diagnostics
Volume17
Issue number11
DOIs
StatePublished - Nov 2 2017

Fingerprint

Fragile X Syndrome
Mosaicism
Methylation
Alleles
Polymerase Chain Reaction
Messenger RNA
Mutation
Southern Blotting
Cognition
Fluorescence
Gene Expression
DNA

Keywords

  • deletion
  • FMR1mRNA
  • FMRP
  • fragile X syndrome
  • methylation
  • mosaicism
  • transcription

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Size and methylation mosaicism in males with Fragile X syndrome. / Jiraanont, Poonnada; Kumar, Madhur; Tang, Hiu Tung; Espinal, Glenda; Hagerman, Paul J; Hagerman, Randi J; Chutabhakdikul, Nuanchan; Tassone, Flora.

In: Expert Review of Molecular Diagnostics, Vol. 17, No. 11, 02.11.2017, p. 1023-1032.

Research output: Contribution to journalArticle

Jiraanont, Poonnada ; Kumar, Madhur ; Tang, Hiu Tung ; Espinal, Glenda ; Hagerman, Paul J ; Hagerman, Randi J ; Chutabhakdikul, Nuanchan ; Tassone, Flora. / Size and methylation mosaicism in males with Fragile X syndrome. In: Expert Review of Molecular Diagnostics. 2017 ; Vol. 17, No. 11. pp. 1023-1032.
@article{dfa2691d9ece41d3b191f1de748551ac,
title = "Size and methylation mosaicism in males with Fragile X syndrome",
abstract = "Background: Size and methylation mosaicism are a common phenomenon in Fragile X syndrome (FXS). Here, the authors report a study on twelve fragile X males with atypical mosaicism, seven of whom presented with autism spectrum disorder. Methods: A combination of Southern Blot and PCR analysis was used for CGG allele sizing and methylation. FMR1 mRNA and FMRP expression were measured by qRT-PCR and by Homogeneous Time Resolved Fluorescence methodology, respectively. Results: DNA analysis showed atypical size- or methylation-mosaicism with both, full mutation and smaller (normal to premutation) alleles, as well as a combination of methylated and unmethylated alleles. Four individuals carried a deletion of the CGG repeat and portions of the flanking regions. The extent of methylation among the participants was reflected in the lower FMR1 mRNA and FMRP expression levels detected in these subjects. Conclusion: Decreased gene expression is likely the main contributor to the cognitive impairment observed in these subjects; although the presence of a normal allele did not appear to compensate for the presence of the full mutation, it correlated with better cognitive function in some but not all of the reported cases emphasizing the complexity of the molecular and clinical profile in FXS.",
keywords = "deletion, FMR1mRNA, FMRP, fragile X syndrome, methylation, mosaicism, transcription",
author = "Poonnada Jiraanont and Madhur Kumar and Tang, {Hiu Tung} and Glenda Espinal and Hagerman, {Paul J} and Hagerman, {Randi J} and Nuanchan Chutabhakdikul and Flora Tassone",
year = "2017",
month = "11",
day = "2",
doi = "10.1080/14737159.2017.1377612",
language = "English (US)",
volume = "17",
pages = "1023--1032",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Size and methylation mosaicism in males with Fragile X syndrome

AU - Jiraanont, Poonnada

AU - Kumar, Madhur

AU - Tang, Hiu Tung

AU - Espinal, Glenda

AU - Hagerman, Paul J

AU - Hagerman, Randi J

AU - Chutabhakdikul, Nuanchan

AU - Tassone, Flora

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Background: Size and methylation mosaicism are a common phenomenon in Fragile X syndrome (FXS). Here, the authors report a study on twelve fragile X males with atypical mosaicism, seven of whom presented with autism spectrum disorder. Methods: A combination of Southern Blot and PCR analysis was used for CGG allele sizing and methylation. FMR1 mRNA and FMRP expression were measured by qRT-PCR and by Homogeneous Time Resolved Fluorescence methodology, respectively. Results: DNA analysis showed atypical size- or methylation-mosaicism with both, full mutation and smaller (normal to premutation) alleles, as well as a combination of methylated and unmethylated alleles. Four individuals carried a deletion of the CGG repeat and portions of the flanking regions. The extent of methylation among the participants was reflected in the lower FMR1 mRNA and FMRP expression levels detected in these subjects. Conclusion: Decreased gene expression is likely the main contributor to the cognitive impairment observed in these subjects; although the presence of a normal allele did not appear to compensate for the presence of the full mutation, it correlated with better cognitive function in some but not all of the reported cases emphasizing the complexity of the molecular and clinical profile in FXS.

AB - Background: Size and methylation mosaicism are a common phenomenon in Fragile X syndrome (FXS). Here, the authors report a study on twelve fragile X males with atypical mosaicism, seven of whom presented with autism spectrum disorder. Methods: A combination of Southern Blot and PCR analysis was used for CGG allele sizing and methylation. FMR1 mRNA and FMRP expression were measured by qRT-PCR and by Homogeneous Time Resolved Fluorescence methodology, respectively. Results: DNA analysis showed atypical size- or methylation-mosaicism with both, full mutation and smaller (normal to premutation) alleles, as well as a combination of methylated and unmethylated alleles. Four individuals carried a deletion of the CGG repeat and portions of the flanking regions. The extent of methylation among the participants was reflected in the lower FMR1 mRNA and FMRP expression levels detected in these subjects. Conclusion: Decreased gene expression is likely the main contributor to the cognitive impairment observed in these subjects; although the presence of a normal allele did not appear to compensate for the presence of the full mutation, it correlated with better cognitive function in some but not all of the reported cases emphasizing the complexity of the molecular and clinical profile in FXS.

KW - deletion

KW - FMR1mRNA

KW - FMRP

KW - fragile X syndrome

KW - methylation

KW - mosaicism

KW - transcription

UR - http://www.scopus.com/inward/record.url?scp=85031405628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031405628&partnerID=8YFLogxK

U2 - 10.1080/14737159.2017.1377612

DO - 10.1080/14737159.2017.1377612

M3 - Article

C2 - 28929824

AN - SCOPUS:85031405628

VL - 17

SP - 1023

EP - 1032

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 11

ER -